British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008

Table of contents 1.0 Introduction 2.0 Methodology 2.1 Basing recommendations on evidence 2.2 Implications for research 2.3 Use of surrogate marker data 2.4 Issues concerning design and analysis of clinical trials 2.4.1 Trial designs 2.4.2 Viral load outcome measures 2.4.3 Noninferiority 2.4.4 Cross-study comparisons and presentation of data 2.5 Adverse event reporting 3.0 When to start 3.1 Primary HIV infection 3.2 Established HIV infection 3.3 Patients with a CD4 count >350 cells/μL 3.4 Comorbidities 4.0 What to start with 4.1 Which HAART regimen is best? 4.2 Recommendations 4.3 Two NRTIs plus an NNRTI 4.3.1 Efavirenz (preferred regimen) 4.3.2 Nevirapine 4.4 Two NRTIs plus a boosted PI 4.4.1 Boosted…

• AL
  Abbott Laboratories
• BS
  Bristol-Myers Squibb
• P
  Pfizer
• G
  GlaxoSmithKline
• S
  Sanofi
• GS
  Gilead Sciences
• UO
  University of Liverpool
• MS
  Merck Sharp and Dohme
• SP
  Sanofi Pasteur
• MR
  Medical Research Council